Supreme Group establishes first U.S. manufacturing facility to strengthen nonwoven materials business

By K. Gopalakrishnan

$25.8 Million Investment in North Carolina to Drive Innovation, Application Development and Customer Collaboration

Supreme Group, one of India’s leading manufacturers of advanced nonwoven materials and engineered textile solutions, has announced a major strategic investment in the United States through its subsidiary, Supreme Nonwoven Inc. The company will invest approximately US$25.8 million to establish its first manufacturing facility in the U.S., marking a significant milestone in its global expansion journey.

Located in Lexington, North Carolina, the new facility will serve as an integrated hub for application engineering, product development, technical collaboration, and manufacturing, enabling the company to strengthen its presence in North America and work more closely with customers across a wide range of industrial and automotive applications.

Amit Kavrie, Managing Director, Supreme Group

The investment underscores Supreme Group’s long-term commitment to the U.S. market and reflects its strategy of bringing advanced material technologies closer to customers while enhancing responsiveness, innovation, and localized manufacturing capabilities.

Building a Stronger Presence in High-Performance Nonwovens

Over nearly four decades, Supreme Group has established a strong reputation in the development and manufacture of advanced nonwoven materials serving diverse sectors including automotive, apparel, filtration, and industrial applications. The company has built a broad technology platform that enables it to transform specialized materials into value-added solutions tailored to customer requirements.

The new manufacturing facility, spanning more than 200,000 square feet, will significantly enhance the company’s ability to collaborate with customers in North America on customized material solutions. By integrating product development, application engineering, and manufacturing under one roof, Supreme aims to accelerate innovation cycles and improve speed-to-market for new products.

According to the company, the facility will play a critical role in strengthening its ability to develop, test, and refine materials closer to their end-use environments.

“Our decision to establish this facility in North Carolina reflects a long-term commitment to serving the U.S. market with locally manufactured nonwoven materials,” said Amit Kavrie, Managing Director, Supreme Group. “We see this as an important step in bringing our material technologies and development capabilities closer to customers in the region while building a foundation for long-term growth.”

Focus on Application Development and Customer-Centric Innovation

A distinguishing feature of the investment is its emphasis on technical collaboration and application-focused innovation. Rather than serving solely as a production facility, the site is being designed as a center where customers and partners can work closely with Supreme’s technical teams to develop customized material solutions for evolving market requirements.

The company believes that proximity to customers will enable a deeper understanding of application challenges while supporting more efficient product trials, validation processes, and commercialization efforts.

In its announcement, Supreme noted that the facility will focus on enhancing performance, consistency, and application relevance across its product portfolio. The local presence is expected to improve alignment with customer requirements and ensure more consistent execution across projects.

“Over time, it will strengthen our ability to develop and trial materials closer to their end use, with a focus on performance, consistency and application relevance,” the company stated.

The investment also reflects Supreme’s intention to establish a stable and scalable manufacturing platform that can evolve in line with future market demand.

Supporting Automotive and Industrial Growth Opportunities

The new U.S. facility is expected to play a key role in serving high-growth sectors such as automotive and industrial manufacturing, where demand for advanced nonwoven materials continues to increase.

As automotive manufacturers seek lighter, more sustainable, and performance-driven material solutions, nonwovens are becoming increasingly important across interior applications, acoustic systems, filtration, insulation, and engineered components. Similarly, industrial markets continue to require specialized nonwoven solutions that combine durability, functionality, and cost efficiency.

By locating closer to major customer bases, Supreme aims to strengthen technical support, improve responsiveness, and create stronger partnerships with OEMs, Tier suppliers, and industrial manufacturers throughout North America.

“Lexington offers us a strong base from which to support customers with responsiveness, technical collaboration, and reliable execution,” said Manoj Swain, Director of International Operations, Supreme Group. “As we build this operation, our focus will be on creating the right competencies locally while also drawing on the broader capabilities of the Group to serve regional customer requirements over time.”

A Strategic Step in Global Expansion

The establishment of the company’s first U.S. manufacturing presence represents far more than a capacity expansion. It reflects Supreme Group’s broader vision of building a globally integrated nonwovens business supported by localized manufacturing, customer collaboration, and innovation-driven growth.

By combining its extensive materials expertise with a strong local presence, the company is positioning itself to serve the evolving needs of North American customers more effectively while strengthening its role in the global nonwovens industry.

As demand for advanced materials continues to grow across automotive, industrial, filtration, and technical textile applications, Supreme Group’s latest investment marks an important step in expanding its international footprint and reinforcing its commitment to delivering high-performance, customer-focused nonwoven solutions worldwide.

Source link

AdvanCell Establishes U.S. Headquarters and Manufacturing Hub in Greater Boston

AdvanCell has established its U.S. Global Headquarters in the Greater Boston area and leased a 128,000-square-foot facility that will serve as its flagship U.S. manufacturing center, a move that expands the clinical-stage radiopharmaceutical company’s North American footprint and supports its long-term commercialization strategy.

The new facility, located at IQHQ’s Innovation Park campus in Andover, Massachusetts, will house both corporate operations and advanced manufacturing capabilities as AdvanCell continues to develop targeted alpha therapies for cancer. The investment marks a significant milestone in the company’s transition toward becoming a U.S.-based radiopharmaceutical organization with integrated operations spanning North America and Australia.

The expansion is designed to support the continued development of ADVC001, the company’s lead prostate cancer program, as well as its broader Lead-212 targeted alpha therapy pipeline. AdvanCell said the Andover site will become its first internal manufacturing facility in the United States, providing infrastructure to support future clinical and commercial production requirements.

“Establishing AdvanCell’s U.S. Global Headquarters and future manufacturing facility reinforces our commitment to U.S. expansion and represents an important milestone in AdvanCell’s strategy to build a global, vertically integrated targeted alpha therapy company,” said Chief Executive Officer Philina Lee, Ph.D.

Lee said the facility will play a central role in scaling production capabilities as the company advances ADVC001 and additional Lead-212 programs through clinical development. She noted that AdvanCell will continue to leverage its Australian operations for clinical translation, isotope supply and manufacturing process innovation while expanding its U.S. presence.

The Greater Boston region has become a major hub for biotechnology and radiopharmaceutical development, offering access to research institutions, manufacturing expertise, specialized talent and a deep life sciences ecosystem. By locating its headquarters and manufacturing operations in the area, AdvanCell gains proximity to key industry partners and resources needed to support future growth.

In addition to the Andover buildout, the company is working with a contract development and manufacturing organization to establish U.S.-based drug product manufacturing capabilities. AdvanCell said the dual-track strategy is expected to accelerate access to manufacturing capacity while the new facility is fitted out and qualified for production.

The approach is intended to support ongoing clinical development, including Phase 2 enrollment in the company’s TheraPb study in the United States, while creating the foundation for future Phase 3 and commercial-scale manufacturing operations.

AdvanCell’s lead candidate, 212Pb-ADVC001, is a prostate-specific membrane antigen (PSMA)-targeting radioligand designed for the treatment of prostate cancer. The therapy uses Lead-212, an alpha-emitting radionuclide with a 10.6-hour half-life, to deliver targeted radiation directly to cancer cells while limiting exposure to surrounding healthy tissue.

The ongoing TheraPb trial is a Phase 1/2 study evaluating ADVC001 in patients with metastatic prostate cancer. Following completion of the Phase 1b dose-escalation portion of the trial, the Phase 2 expansion stage is evaluating efficacy and safety across two dose levels. The study includes patients with PSMA-positive metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer.

Radiopharmaceutical development has emerged as one of the fastest-growing segments within oncology, driving increased investment in manufacturing infrastructure as companies seek to secure isotope supply chains and production capacity. Because radiopharmaceuticals have short shelf lives and complex production requirements, manufacturing scale and geographic reach are increasingly viewed as critical components of commercialization readiness.

For AdvanCell, the establishment of a U.S. headquarters and large-scale manufacturing facility represents a strategic investment in both operational infrastructure and future market access as it advances its targeted alpha therapy platform toward later-stage development and potential commercialization.

Source link

Samsung Biologics establishes first U.S. manufacturing base with acquisition of GSK site – Chemical Engineering

April 3, 2026 | By Mary Bailey

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.

The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters.

Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional contract manufacturing needs. Samsung Biologics also plans further investments to expand the site’s capacity and upgrade technologies, reinforcing its long-term commitment to advancing a more resilient global supply chain and improving patient access to critical medicines.

“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family,” said John Rim, President and CEO of Samsung Biologics. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.”

The completion follows the previously announced agreement to acquire the facility on December 22, 2025.

Source link